Encapsulated islet transplantation
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Pancreatic function and diabetes · Diabetes Management and Research · Diabetes and associated disorders
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Foster, N. C. et al. State of type 1 diabetes management and outcomes from the T1D exchange in 2016–2018. Diabetes Technol. Ther. 21, 66–72 (2019).10.1089/dia.2018.0384 ↗
2. Atkinson, M. A., Eisenbarth, G. S. & Michels, A. W. Type 1 diabetes. Lancet 383, 69–82 (2014).10.1016/S0140-6736(13)60591-7 ↗
3. Shapiro, A. M. J. et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N. Engl. J. Med. 343, 230–238 (2000).10.1056/NEJM200007273430401 ↗
4. Ryan, E. A. et al. Five-year follow-up after clinical islet transplantation. Diabetes 54, 2060–2069 (2005).10.2337/diabetes.54.7.2060 ↗
5. Berney, T. et al. A worldwide survey of activities and practices in clinical islet of Langerhans transplantation. Transpl. Int. 35, 10507 (2022).10.3389/ti.2022.10507 ↗
6. Stabler, C. L. & Russ, H. A. Regulatory approval of islet transplantation for treatment of type 1 diabetes: implications and what is on the horizon. Mol. Ther. 31, 3107–3108 (2023).10.1016/j.ymthe.2023.10.011 ↗
7. Cnop, M. et al. Longevity of human islet α- and β-cells. Diabetes Obes. Metab. 13, 39–46 (2011).10.1111/j.1463-1326.2011.01443.x ↗
8. Carlsson, P.-O. et al. Transplantation of macroencapsulated human islets within the bioartificial pancreas βAir to patients with type 1 diabetes mellitus. Am. J. Transplant. 18, 1735–1744 (2018).10.1111/ajt.14642 ↗
9. Shapiro, A. M. J. et al. Insulin expression and C-peptide in type 1 diabetes subjects implanted with stem cell-derived pancreatic endoderm cells in an encapsulation device. Cell Rep. Med. 2, 100466 (2021).10.1016/j.xcrm.2021.100466 ↗
10. Basta, G. et al. Long-term metabolic and immunological follow-up of nonimmunosuppressed patients with type 1 diabetes treated with microencapsulated islet allografts. Diabetes Care 34, 2406–2409 (2011).10.2337/dc11-0731 ↗
11. Li, Y. et al. In vitro platform establishes antigen-specific CD8+ T cell cytotoxicity to encapsulated cells via indirect antigen recognition. Biomaterials 256, 120182 (2020).10.1016/j.biomaterials.2020.120182 ↗
12. Jones, K. S., Sefton, M. V. & Gorczynski, R. M. In vivo recognition by the host adaptive immune system of microencapsulated xenogeneic cells. Transplantation 78, 1454–1462 (2004).10.1097/01.TP.0000142094.63083.FB ↗
13. Kobayashi, T. et al. Immune mechanisms associated with the rejection of encapsulated neonatal porcine islet xenografts. Xenotransplantation 13, 547–559 (2006).10.1111/j.1399-3089.2006.00349.x ↗
14. Duvivier-Kali, V. F., Omer, A., Lopez-Avalos, M. D., O’Neil, J. J. & Weir, G. C. Survival of microencapsulated adult pig islets in mice in spite of an antibody response. Am. J. Transplant. 4, 1991–2000 (2004).10.1111/j.1600-6143.2004.00628.x ↗
15. Kharbikar, B. N., Chendke, G. S. & Desai, T. A. Modulating the foreign body response of implants for diabetes treatment. Adv. Drug. Deliv. Rev. 174, 87–113 (2021).10.1016/j.addr.2021.01.011 ↗
16. Veiseh, O. et al. Size- and shape-dependent foreign body immune response to materials implanted in rodents and non-human primates. Nat. Mater. 14, 643–651 (2015).10.1038/nmat4290 ↗
17. Chang, T. M. S. Semipermeable microcapsules. Science 146, 524–525 (1964).10.1126/science.146.3643.524 ↗
18. Lim, F. & Sun Anthony, M. Microencapsulated islets as bioartificial endocrine pancreas. Science 210, 908–910 (1980).10.1126/science.6776628 ↗
19. Lee, S. J., Lee, J. B., Park, Y.-W. & Lee, D. Y. In Biomimetic Medical Materials: from Nanotechnology to 3D Bioprinting (ed. Noh, I.) 355–374 (Springer Singapore, 2018).10.1007/978-981-13-0445-3_21 ↗
20. Kizilel, S., Garfinkel, M. & Opara, E. The bioartificial pancreas: progress and challenges. Diabetes Technol. Ther. 7, 968–985 (2005).10.1089/dia.2005.7.968 ↗
21. Sakata, N. et al. MRI assessment of ischemic liver after intraportal islet transplantation. Transplantation 87, 825–830 (2009).10.1097/TP.0b013e318199c7d2 ↗
22. Chen, C. et al. Improved intraportal islet transplantation outcome by systemic IKK-β inhibition: NF-κB activity in pancreatic islets depends on oxygen availability. Am. J. Transplant. 11, 215–224 (2011).10.1111/j.1600-6143.2010.03390.x ↗
23. Olsson, R., Olerud, J., Pettersson, U. & Carlsson, P. O. Increased numbers of low-oxygenated pancreatic islets after intraportal islet transplantation. Diabetes 60, 2350–2353 (2011).10.2337/db09-0490 ↗
24. Shapiro, A. M. J., Pokrywczynska, M. & Ricordi, C. Clinical pancreatic islet transplantation. Nat. Rev. Endocrinol. 13, 268–277 (2017).10.1038/nrendo.2016.178 ↗
25. Qi, M. et al. A recommended laparoscopic procedure for implantation of microcapsules in the peritoneal cavity of non-human primates. J. Surg. Res. 168, e117–e123 (2011).10.1016/j.jss.2011.01.040 ↗
26. Bochenek, M. A. et al. Alginate encapsulation as long-term immune protection of allogeneic pancreatic islet cells transplanted into the omental bursa of macaques. Nat. Biomed. Eng. 2, 810–821 (2018).10.1038/s41551-018-0275-1 ↗
27. Damyar, K., Farahmand, V., Whaley, D., Alexander, M. & Lakey, J. R. T. An overview of current advancements in pancreatic islet transplantation into the omentum. Islets 13, 115–120 (2021).10.1080/19382014.2021.1954459 ↗
28. Berman, D. M. et al. Long-term survival of nonhuman primate islets implanted in an omental pouch on a biodegradable scaffold. Am. J. Transplant. 9, 91–104 (2008).10.1111/j.1600-6143.2008.02489.x ↗
29. Carlsson, P.-O., Palm, F., Andersson, A. & Liss, P. Markedly decreased oxygen tension in transplanted rat pancreatic islets irrespective of the implantation site. Diabetes 50, 489–495 (2001).10.2337/diabetes.50.3.489 ↗
30. Cao, R., Avgoustiniatos, E., Papas, K., Vos, P. & Lakey, J. R. T. Mathematical predictions of oxygen availability in micro‐ and macro‐encapsulated human and porcine pancreatic islets. J. Biomed. Mater. Res. B 108, 343–352 (2019).10.1002/jbm.b.34393 ↗
31. Korsgren, O. Islet encapsulation: physiological possibilities and limitations. Diabetes 66, 1748–1754 (2017).10.2337/db17-0065 ↗
32. Gilla, R. G. Antigen presentation pathways for immunity to islet transplants: relevance to immunoisolation. Ann. NY Acad. Sci. 875, 255–260 (1999).10.1111/j.1749-6632.1999.tb08508.x ↗
33. Gray, D. W. R. An overview of the immune system with specific reference to membrane encapsulation and islet transplantation. Ann. NY Acad. Sci. 944, 226–239 (2001).10.1111/j.1749-6632.2001.tb03835.x ↗
34. Brauker, J., Martinson, L. A., Young, S. K. & Johnson, R. C. Local inflammatory response around diffusion chambers containing xenografts. Transplantation 61, 1671–1677 (1996).10.1097/00007890-199606270-00002 ↗
35. Kumagai-Braesch, M. et al. The TheraCyte™ device protects against islet allograft rejection in immunized hosts. Cell Transpl. 22, 1137–1146 (2013).10.3727/096368912X657486 ↗
36. Loudovaris, T., Mandel, T. E. & Charlton, B. Cd4+ T cell mediated destruction of xenografts within cell-impermeable membranes in the absence of Cd8+ T cells and B cells. Transplantation 61, 1678–1684 (1996).10.1097/00007890-199606270-00003 ↗
37. Rayat, G. R. et al. The degree of phylogenetic disparity of islet grafts dictates the reliance on indirect CD4 T-cell antigen recognition for rejection. Diabetes 52, 1433–1440 (2003).10.2337/diabetes.52.6.1433 ↗
38. Gray, D. W. R. Encapsulated islet cells: the role of direct and indirect presentation and the relevance to xenotransplantation and autoimmune recurrence. Br. Med. Bull. 53, 777–788 (1997).10.1093/oxfordjournals.bmb.a011647 ↗
39. O’Shea, G. M., Goosen, M. F. A. & Sun, A. M. Prolonged survival of transplanted islets of Langerhans encapsulated in a biocompatible membrane. Biochim. Biophys. Acta 804, 133–136 (1984).10.1016/0167-4889(84)90107-1 ↗
40. Kollmer, M., Appel, A. A., Somo, S. I. & Brey, E. M. Long-term function of alginate-encapsulated islets. Tissue Eng. B 22, 34–46 (2016).10.1089/ten.teb.2015.0140 ↗
41. Ching, S. H., Bansal, N. & Bhandari, B. Alginate gel particles — a review of production techniques and physical properties. Crit. Rev. Food Sci. Nutr. 57, 1133–1152 (2015).10.1080/10408398.2014.965773 ↗
42. Dhamecha, D., Movsas, R., Sano, U. & Menon, J. U. Applications of alginate microspheres in therapeutics delivery and cell culture: past, present and future. Int. J. Pharm. 569, 118627 (2019).10.1016/j.ijpharm.2019.118627 ↗
43. King, A., Lau, J., Nordin, A., Sandler, S. & Andersson, A. The effect of capsule composition in the reversal of hyperglycemia in diabetic mice transplanted with microencapsulated allogeneic islets. Diabetes Technol. Ther. 5, 653–663 (2003).10.1089/152091503322250677 ↗
44. Clayton, H. A., London, N. J. M., Colloby, P. S., Bell, P. R. F. & James, R. F. L. The effect of capsule composition on the biocompatibility of alginate-poly-1-lysine capsules. J. Microencapsul. 8, 221–233 (2008).10.3109/02652049109071490 ↗
45. King, A., Sandler, S. & Andersson, A. The effect of host factors and capsule composition on the cellular overgrowth on implanted alginate capsules. J. Biomed. Mater. Res. 57, 374–383 (2001).10.1002/1097-4636(20011205)57:3<374::AID-JBM1180>3.0.CO;2-L ↗
46. Thu, B. et al. Alginate polycation microcapsules. Biomaterials 17, 1031–1040 (1996).10.1016/0142-9612(96)84680-1 ↗
47. Strand, B. L. et al. Poly-l-lysine induces fibrosis on alginate microcapsules via the induction of cytokines. Cell Transpl. 10, 263–275 (2017).10.3727/000000001783986800 ↗
48. Sawhney, A. S., Pathak, C. P. & Hubbell, J. A. Modification of islet of Langerhans surfaces with immunoprotective poly(ethylene glycol) coatings via interfacial photopolymerization. Biotechnol. Bioeng. 44, 383–386 (1994).10.1002/bit.260440317 ↗
49. Cruise, G. M., Hegre, O. D., Scharp, D. S. & Hubbell, J. A. A sensitivity study of the key parameters in the interfacial photopolymerization of poly(ethylene glycol) diacrylate upon porcine islets. Biotechnol. Bioeng. 57, 655–665 (1998).10.1002/(SICI)1097-0290(19980320)57:6<655::AID-BIT3>3.0.CO;2-K ↗
50. Scharp, D. W. & Marchetti, P. Encapsulated islets for diabetes therapy: history, current progress, and critical issues requiring solution. Adv. Drug. Del. Rev. 67-–68, 35–73 (2014).10.1016/j.addr.2013.07.018 ↗
51. Teramura, Y. & Iwata, H. Bioartificial pancreas: microencapsulation and conformal coating of islet of Langerhans. Adv. Drug. Del. Rev. 62, 827–840 (2010).10.1016/j.addr.2010.01.005 ↗
52. Zhi, Z.-L., Liu, B., Jones, P. M. & Pickup, J. C. Polysaccharide multilayer nanoencapsulation of insulin-producing β-cells grown as pseudoislets for potential cellular delivery of insulin. Biomacromolecules 11, 610–616 (2010).10.1021/bm901152k ↗
53. Zhi, Z. L., Kerby, A., King, A. J. F., Jones, P. M. & Pickup, J. C. Nano-scale encapsulation enhances allograft survival and function of islets transplanted in a mouse model of diabetes. Diabetologia 55, 1081–1090 (2012).10.1007/s00125-011-2431-y ↗
54. Bhaiji, T., Zhi, Z.-L. & Pickup, J. C. Improving cellular function and immune protection via layer-by-layer nanocoating of pancreatic islet β-cell spheroids cocultured with mesenchymal stem cells. J. Biomed. Mater. Res. A 100A, 1628–1636 (2012).10.1002/jbm.a.34111 ↗
55. Fischer, D., Li, Y., Ahlemeyer, B., Krieglstein, J. & Kissel, T. In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis. Biomaterials 24, 1121–1131 (2003).10.1016/S0142-9612(02)00445-3 ↗
56. Chanana, M. et al. Interaction of polyelectrolytes and their composites with living cells. Nano Lett. 5, 2605–2612 (2005).10.1021/nl0521219 ↗
57. Teramura, Y. & Iwata, H. Cell surface modification with polymers for biomedical studies. Soft Matter. 6, 1081–1091 (2010).10.1039/b913621e ↗
58. Song, S. & Roy, S. Progress and challenges in macroencapsulation approaches for type 1 diabetes (T1D) treatment: cells, biomaterials, and devices. Biotechnol. Bioeng. 113, 1381–1402 (2016).10.1002/bit.25895 ↗
59. Brauker, J. H. et al. Neovascularization of synthetic membranes directed by membrane microarchitecture. J. Biomed. Mater. Res. 29, 1517–1524 (1995).10.1002/jbm.820291208 ↗
60. Faleo, G., Lee, K., Nguyen, V. & Tang, Q. Assessment of immune isolation of allogeneic mouse pancreatic progenitor cells by a macroencapsulation device. Transplantation 100, 1211–1218 (2016).10.1097/TP.0000000000001146 ↗
61. Agulnick, A. D. et al. Insulin-producing endocrine cells differentiated in vitro from human embryonic stem cells function in macroencapsulation devices in vivo. Stem Cell Transl. Med. 4, 1214–1222 (2015).10.5966/sctm.2015-0079 ↗
62. Pullen, L. C. Stem cell-derived pancreatic progenitor cells have now been transplanted into patients: report from IPITA 2018. Am. J. Transplant. 18, 1581–1582 (2018).10.1111/ajt.14954 ↗
63. Henry, R. R. et al. Initial clinical evaluation of VC-01TM combination product — a stem cell-derived islet replacement for type 1 diabetes (T1D). Diabetes 67 (Suppl. 1), 138-OR (2018).10.2337/db18-138-OR ↗
64. ClinicalTrials.gov A safety, tolerability, and efficacy study of VC-01™ combination product in subjects with type I diabetes mellitus. US National Library of Medicine https://clinicaltrials.gov/ct2/show/results/NCT02239354 (2022).
65. ClinicalTrials.gov A study to evaluate safety, engraftment, and efficacy of VC-01 in subjects with T1 diabetes mellitus (VC01-103). US National Library of Medicine https://classic.clinicaltrials.gov/ct2/show/NCT04678557 (2019).
66. Maki, T. et al. Successful treatment of diabetes with the biohybrid artificial pancreas in dogs. Transplantation 51, 43–50 (1991).10.1097/00007890-199101000-00006 ↗
67. Sullivan, S. et al. Biohybrid artificial pancreas: long-term implantation studies in diabetic, pancreatectomized dogs. Science 252, 718–721 (1991).10.1126/science.2024124 ↗
68. Maki, T. et al. Treatment of diabetes by xenogeneic islets without immunosuppression: use of a vascularized bioartificial pancreas. Diabetes 45, 342–347 (1996).10.2337/diab.45.3.342 ↗
69. Yang, K. et al. A therapeutic convection-enhanced macroencapsulation device for enhancing β cell viability and insulin secretion. Proc. Natl Acad. Sci. USA 118, e2101258118 (2021).
70. Oppler, S. H. et al. A bioengineered artificial interstitium supports long-term islet xenograft survival in nonhuman primates without immunosuppression. Sci. Adv. 10, eadi4919 (2024).10.1126/sciadv.adi4919 ↗
71. Hilburger, C. E., Rosenwasser, M. J. & Delcassian, D. The type 1 diabetes immune niche: immunomodulatory biomaterial design considerations for beta cell transplant therapies. J. Immunol. Regen. Med. 17, 100063 (2022).
72. Gibly, R. F. et al. Advancing islet transplantation: from engraftment to the immune response. Diabetologia 54, 2494–2505 (2011).10.1007/s00125-011-2243-0 ↗
73. Chandorkar, Y., Ravikumar, K. & Basu, B. The foreign body response demystified. ACS Biomater. Sci. Eng. 5, 19–44 (2018).10.1021/acsbiomaterials.8b00252 ↗
74. Mariani, E., Lisignoli, G., Borzì, R. M. & Pulsatelli, L. Biomaterials: foreign bodies or tuners for the immune response? Int. J. Mol. Sci. 20, 636 (2019).10.3390/ijms20030636 ↗
75. Rafael, E., Wernerson, A., Arner, P., Wu, G. S. & Tibell, A. In vivo evaluation of glucose permeability of an immunoisolation device intended for islet transplantation: a novel application of the microdialysis technique. Cell Transpl. 8, 317–326 (1999).10.1177/096368979900800302 ↗
76. Matsumoto, S. et al. Clinical porcine islet xenotransplantation under comprehensive regulation. Transplant. Proc. 46, 1992–1995 (2014).10.1016/j.transproceed.2014.06.008 ↗
77. Matsumoto, S., Abalovich, A., Wechsler, C., Wynyard, S. & Elliott, R. B. Clinical benefit of islet xenotransplantation for the treatment of type 1 diabetes. eBioMedicine 12, 255–262 (2016).10.1016/j.ebiom.2016.08.034 ↗
78. Morozov, V. A. et al. No PERV transmission during a clinical trial of pig islet cell transplantation. Virus Res. 227, 34–40 (2017).10.1016/j.virusres.2016.08.012 ↗
79. Elliott, R. B. et al. Transplantation of micro- and macroencapsulated piglet islets into mice and monkeys. Transplant. Proc. 37, 466–469 (2005).10.1016/j.transproceed.2004.12.198 ↗
80. Elliott, R. B. et al. Intraperitoneal alginate-encapsulated neonatal porcine islets in a placebo-controlled study with 16 diabetic cynomolgus primates. Transplant. Proc. 37, 3505–3508 (2005).10.1016/j.transproceed.2005.09.038 ↗
81. Doloff, J. C. et al. Colony stimulating factor-1 receptor is a central component of the foreign body response to biomaterial implants in rodents and non-human primates. Nat. Mater. 16, 671–680 (2017).10.1038/nmat4866 ↗
82. Dondossola, E. et al. Examination of the foreign body response to biomaterials by nonlinear intravital microscopy. Nat. Biomed. Eng. 1, 0007 (2016).10.1038/s41551-016-0007 ↗
83. Vegas, A. J. et al. Combinatorial hydrogel library enables identification of materials that mitigate the foreign body response in primates. Nat. Biotechnol. 34, 345–352 (2016).10.1038/nbt.3462 ↗
84. Vegas, A. J. et al. Long-term glycemic control using polymer-encapsulated human stem cell-derived β cells in immune-competent mice. Nat. Med. 22, 306–311 (2016).10.1038/nm.4030 ↗
85. Bose, S. et al. A retrievable implant for the long-term encapsulation and survival of therapeutic xenogeneic cells. Nat. Biomed. Eng. 4, 814–826 (2020).10.1038/s41551-020-0538-5 ↗
86. Liu, Q. et al. Zwitterionically modified alginates mitigate cellular overgrowth for cell encapsulation. Nat. Commun. 10, 5262 (2019).
87. Liu, W. et al. A safe, fibrosis-mitigating, and scalable encapsulation device supports long-term function of insulin-producing cells. Small 18, e2104899 (2022).
88. Liu, Q. et al. A zwitterionic polyurethane nanoporous device with low foreign‐body response for islet encapsulation. Adv. Mater. 33, e2102852 (2021).
89. Chen, T. et al. Alginate encapsulant incorporating CXCL12 supports long-term allo- and xenoislet transplantation without systemic immune suppression. Am. J. Transplant. 15, 618–627 (2015).10.1111/ajt.13049 ↗
90. Alagpulinsa, D. A. et al. Alginate‐microencapsulation of human stem cell-derived β cells with CXCL12 prolongs their survival and function in immunocompetent mice without systemic immunosuppression. Am. J. Transplant. 197, 1930–1940 (2019).10.1111/ajt.15308 ↗
91. Sremac, M. et al. Preliminary studies of the impact of CXCL12 on the foreign body reaction to pancreatic islets microencapsulated in alginate in nonhuman primates. Transplant. Direct 5, e447 (2019).10.1097/TXD.0000000000000890 ↗
92. Su, J., Hu, B.-H., Lowe, W. L., Kaufman, D. B. & Messersmith, P. B. Anti-inflammatory peptide-functionalized hydrogels for insulin-secreting cell encapsulation. Biomaterials 31, 308–314 (2010).10.1016/j.biomaterials.2009.09.045 ↗
93. Lin, C.-C., Metters, A. T. & Anseth, K. S. Functional PEG–peptide hydrogels to modulate local inflammation induced by the pro-inflammatory cytokine TNFα. Biomaterials 30, 4907–4914 (2009).10.1016/j.biomaterials.2009.05.083 ↗
94. Kuppan, P. et al. Co‐localized immune protection using dexamethasone‐eluting micelles in a murine islet allograft model. Am. J. Transplant. 20, 714–725 (2019).10.1111/ajt.15662 ↗
95. Bünger, C. M. et al. Deletion of the tissue response against alginate-PLL capsules by temporary release of co-encapsulated steroids. Biomaterials 26, 2353–2360 (2005).10.1016/j.biomaterials.2004.07.017 ↗
96. Jiang, K. et al. Local release of dexamethasone from macroporous scaffolds accelerates islet transplant engraftment by promotion of anti-inflammatory M2 macrophages. Biomaterials 114, 71–81 (2017).10.1016/j.biomaterials.2016.11.004 ↗
97. Weaver, J. D. et al. Controlled release of dexamethasone from organosilicone constructs for local modulation of inflammation in islet transplantation. Tissue Eng. A 21, 2250–2261 (2015).10.1089/ten.tea.2014.0487 ↗
98. Primavera, R. et al. Enhancing islet transplantation using a biocompatible collagen-PDMS bioscaffold enriched with dexamethasone-microplates. Biofabrication 13, 035011 (2021).10.1088/1758-5090/abdcac ↗
99. Veiseh, O. & Vegas, A. J. Domesticating the foreign body response: recent advances and applications. Adv. Drug. Del. Rev. 144, 148–161 (2019).10.1016/j.addr.2019.08.010 ↗
100. Ranta, F. et al. Dexamethasone induces cell death in insulin-secreting cells, an effect reversed by exendin-4. Diabetes 55, 1380–1390 (2006).10.2337/db05-1220 ↗